Introduction: Dry eye disease is one of the most common ocular surface diseases in India and worldwide ; particularly in the post-menopausal women and elderly. It occurs when there is inadequate tear volume or function resulting in an unstable tear film and ocular surface disease.(1) The early detection and timely management of this disease is important to prevent long term sequelae and sight threatening complications. Multiple approaches which include drugs like Cyclosporine and Rebamipide are required to manage cases of moderate to severe dry eye disease. Objectives: 1.To study socio demographic profile of patients with dry eye. 2. To compare the effectiveness of Cyclosporine 0.1% eye drops and Rebamipide 2% eye drops in treatment of dry eye. 3. To suggest suitable recommendations based on study finding. Methodology: The study subjects were divided into two groups one of which received Cyclosporine 0.1% while the other group got Rebamipide 2% eye drops. Both groups were assesed based on Schirmer’s test, OSDI score and TBUT over a period of 6 months along with their demographic characteristics and a statistical analysis of the comparison of the two drugs was drawn. Results: Based on the Schirmer’s score, OSDI score and TBUT, Rebamipide is showing more promising results with lesser side effects as compared to Cyclosporine. Conclusion: Rebamipide 2% eye drop can be safely used in the long term management of moderate to severe dry eye cases.
Key Words: Cyclosporine, Rebamipide, Schirmer’s, OSDI, TBUT.
Received: 14 December 2018 Revised: 27 December 2018 Accepted: 28 December 2018
Corresponding author: Dr. Avani Patil, Post Graduate Student, Department of Ophthalmology, D.Y. Patil Hospital and Research Institute, Kolhapur, Maharashtra, India
This article may be cited as: Patil A, Sabnis M. A Comparative Study between Efficacy of Cyclosporine 0.1% and Rebamipide 2% Eye Drops in Moderate to Severe Dry Eye Cases. J Adv Med Dent Scie Res 2019;7(1):86-92.